[go: up one dir, main page]

EP1183514A1 - Dispositif de traitement d'echantillons - Google Patents

Dispositif de traitement d'echantillons

Info

Publication number
EP1183514A1
EP1183514A1 EP00937072A EP00937072A EP1183514A1 EP 1183514 A1 EP1183514 A1 EP 1183514A1 EP 00937072 A EP00937072 A EP 00937072A EP 00937072 A EP00937072 A EP 00937072A EP 1183514 A1 EP1183514 A1 EP 1183514A1
Authority
EP
European Patent Office
Prior art keywords
solid phase
liquid
syringe
piston
cartridge
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00937072A
Other languages
German (de)
English (en)
Inventor
Matthew John Baker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Technologies Corp
Original Assignee
DNA Research Innovations Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DNA Research Innovations Ltd filed Critical DNA Research Innovations Ltd
Publication of EP1183514A1 publication Critical patent/EP1183514A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
    • G01N1/40—Concentrating samples
    • G01N1/405—Concentrating samples by adsorption or absorption

Definitions

  • the present invention relates to a sample processing device and in particular to a sample processing device that can purify biomolecules from crude starting materials such as blood, tissue, plants, microbes, agricultural, food etc.
  • the system can also be used to purify or manipulate any biomolecule or compound from aqueous or non- aqueous samples in a fully automated or manual mode.
  • Clogging of columns or cartridges may be due to frits (a thick, rigid, porous disc/membrane or plug) with small pore sizes or the small size of standard solid phase particles (usually less than 200 microns in diameter) and/or close packing of stationary solid phase material (dependant on size and shape and compressibility).
  • frits a thick, rigid, porous disc/membrane or plug
  • small pore sizes or the small size of standard solid phase particles usually less than 200 microns in diameter
  • close packing of stationary solid phase material dependant on size and shape and compressibility
  • equipment for extracting a material from a liquid mixture containing the material which equipment comprises a container containing a solid phase able to adsorb the material to be extracted and a reversible suction means adapted to apply suction to the solid phase to draw up the liquid mixture over the solid phase and which is able to be reversed so as to pass the liquid back over the solid phase.
  • the reversible suction means can be in the form of a syringe and the solid phase is contained within the syringe below the piston so that when the nozzle of the syringe is placed in the liquid mixture and the piston is withdrawn liquid is drawn up over the solid phase and when the piston is depressed the liquid is passed back over the solid phase.
  • the container containing the solid phase can be attached to the nozzle of a syringe.
  • the reversible suction means comprises a pipette and there is a plug of the solid phase contained within the pipette tip.
  • the novel design allows almost any starting material to be used without clogging the automated extraction system and in a closed environment reducing the risks of contamination to the operator, instrument or to adjacent sample tubes.
  • the design allows the use of existing solid phase extraction methods used in chromatography as well as novel reagents and materials described below.
  • the invention is especially suitable for extracting large macromolecules such as nucleic acids (DNA and RNA) that tend to block or clog existing devices.
  • DNA and RNA nucleic acids
  • the syringe or pumping device with sucking and blowing action can be used in conjunction with a specially modified chromatography cartridge that resists clogging.
  • a biological sample e.g. animal or plant tissue, blood, cells, hair, faeces, agricultural, water, food etc. is homogenised to release the nucleic acids and then passed through a solid phase material to capture the nucleic acids, nuclei or nucleated cells.
  • the cellular debris or contaminants pass up and down to waste leaving the nucleic acids immobilised on the solid phase support.
  • the solid-phase material can be used to remove unwanted cellular debris leaving the DNA or biomolecule in solution.
  • the material to be extracted can be passed up and down the solid phase using the pumping action of the syringe or peristaltic pump. Any type of solid phase can be used since the cartridges are designed to be interchangeable for a wide variety of solid phase extractions.
  • the system will allow homogenisation of samples by introducing a shredding device in the primary cartridge.
  • An enrichment step is often used to remove initial debris and this can be performed using flocculating agents such as cellulose, diatomaceous earth, silica gel, dextrans, PEG or any substance that promotes rapid flocculation and sedimentation of debris or contaminants without requiring centrifugation.
  • flocculating agents such as cellulose, diatomaceous earth, silica gel, dextrans, PEG or any substance that promotes rapid flocculation and sedimentation of debris or contaminants without requiring centrifugation.
  • a whole microtitre plate can be processed containing small samples e.g. 1ml buccal cell scrapes, using smaller syringes or pumping devices.
  • UV spectrophotometers require a relatively large sample to analyse in a silica quartz cuvette.
  • the amount of analyte is often in tiny volumes or low concentration. This results in either sacrificing the whole sample or diluting into a bigger volumes which then may make detection very difficult.
  • a disposable probe that dips into the sample the solution can be measured at full strength and without wastage.
  • the instrument design allows incorporation of electrodes or metal meshes or conductive plastic meshes that can be made positively charged to bind nucleic acids from crude extracts. The positive charge can then be turned off or reversed to release the purified nucleic acids.
  • the pumping effect of the instrument allows rapid mixing increasing the contact of the target molecules.
  • porous plastic beads with a diameter of 150microns or greater with very large pores e.g. 1 to 20 microns, made from polypropylene, polyethylene or any polymer with a natural affinity for specific biomolecules.
  • Other materials can also be used; cellulose, agarose, glass, silica or any suitable material that may be derivatised to extract a target analyte.
  • the solid-phase may be derivatised with imidazole groups, amine, carboxy or any group with an affinity for nucleic acids or the target molecule/compound.
  • the beads may be used with a frit or membrane or a single hole or multi hole mesh depending on the flow rates required.
  • the beads may be composed of material that has an inherent affinity of biomolecules such as poly vinyl pyridine that is positively charged at pH 4 and will bind DNA and elute it at pH 8.
  • Any polymeric compound can be converted into beads or particles or surfaces for binding and may include groups such as pyrazole, pyrole, pyrroldine, indole, pyrimidine, nucleic acid bases, imidazole, imines, amines, lysines or any groups that have a pKa in the range of 3 to 12.
  • a pKa of 5 to 8 is employed to maintain physiological conditions if biological samples are being processed and can thus be manipulated by pH to turn a positive charge on or off.
  • the beads may also be converted for chelation of biomolecules such as iminodiacetic acid beads bound with ferric ions at pH 3 to bind nucleic acids. Raising the pH removes the purified nucleic acids. Calcium, Magnesium or Ammonium ions can also be used to chelate biomolecules.
  • the beads can be held stationary using frits or membranes as long as the pore diameters are large enough to allow easy passage of crude matter. In most cases the frits or membranes require relatively large holes (pin holes) not found in conventional materials. Alternatively the beads may be held in place by narrowing the inlet and outlet of the cartridge removing the need for frits or they may be held in place by a mesh incorporated into the design of the cartridge.
  • the larger beads can be allowed to move inside the column by having space inside the cartridge. This helps with mixing and reduces clogging.
  • the beads can be added to the crude mixture as a suspension and then trapped in a cartridge when the target molecules are bound thus achieving separation.
  • Non-porous magnetic (paramagnetic) beads are less than 50microns but are difficult to handle when extracting genomic or microbial DNA. Large porous magnetic beads may lead to internal entrapment of contaminants as the macromolecule such as DNA bind to the outer surface of the beads, these contaminants are only released when the DNA is eluted contaminating the final preparation.
  • Porous membranes or frits can be modified by adding larger holes and used in spaced stacks or individually to bind biomolecules from crude extracts, e.g. blood.
  • Existing membranes or frits block instantly when encountering crude extracts or high molecular weight DNA.
  • the invention describes the use of a unique pore size modification that allows the treatment of crude materials in large or small volumes that is also amenable to automation.
  • a small or large device can be constructed based on the same design.
  • the small device relies on a standard plastic pipette tip that incorporates a single porous plug, wadding, or frit with a pore size that prevents blocking.
  • This can be used with a conventional pipette or syringe in a manual mode or in a fully automated pipetting station.
  • they can be incorporated into Deep Well plates, Microtitre plates or PCR tubes and used with centrifugation or vacuum manifolds.
  • the frits may also be incorporated directly inside a syringe 1ml to 60ml instead of an extra cartridge.
  • the material for the membrane or frit may be porous polyethylene with a primary pore size of 1 to 200 microns or preferably 20 microns , or any porous plastic, porous glass, cellulose with pores large enough to allow passage of crude matter. E.g. 20 microns or larger.
  • the material may have small pore sizes that will enable binding of target molecule, but they must also possess larger holes e.g. 0.1 mm or greater to avoid blocking. This larger hole may be at the edges or in the middle or part of a cut away section.
  • This technique can be assisted by using a filter-aid such as silica gel, titanium oxide, fibrous cellulose etc.
  • a filter-aid is added to flocculate and compact the debris at the bottom of the tube leaving the target molecule in the supernatant ready for processing or purification.
  • the filter-aid may be soluble, possess temperature dependant solubility or be insoluble.
  • a by-pass channel can be introduced that allows larger particles or debris to pass up and down without clogging the cartridge.
  • a bypass channel may be created as small tube that by passes the solid phase or a porous material with large pores e.g. 20 microns or greater, that surrounds the solid phase.
  • solid-phase beads are employed for conventional extractions. For example, less than 100 micron glass, then the solid -phase can be allowed to move internally so clogging is avoided.
  • the introduction of ridges, spirals or obstructions inside the cartridge helps prevent the solid-phase moving in bulk maintaining good mixing and separation of solid-phase. If the solid-phase particles are large enough of sufficiently dense, e.g. 200 micron glass, a mini-fluidised bed can be generated.
  • Clogging of cartridges may also be avoided by the pre-addition of a mobile solid- phase to capture the target molecule.
  • the loose solid-phase or paramagnetic beads are added as a suspension and the contaminants are washed away leaving the immobilised target compound ready for further purification in a cartridge or analysis.
  • Any type of solid phase can be added with a preference for material that will sediment quickly or be flocculated by filter aids to avoid centrifugation or are paramagnetic.
  • the instrument and disposable cartridge or tip system has a variety of applications including molecular biology such as affinity purification of cell antibodies, enzymes and other proteins, purging of mixtures to remove unwanted compounds, combinatorial chemistry, ion exchange purification, hydrophobic chromatography, enzyme assays using immobilised antibodies, nucleic acids or antigens, enzyme catalysis on solid phase supports, food screening for pathogens, genomic DNA, toxins, allergens, etc., clinical sample processing for pathogenic organisms, mixing adjuvants for immunisation and making stable emulsions, pipetting larger volumes, removal of lipoproteins for cholesterol assays, detecting or concentrating pathogens in milk, food or water.
  • molecular biology such as affinity purification of cell antibodies, enzymes and other proteins, purging of mixtures to remove unwanted compounds, combinatorial chemistry, ion exchange purification, hydrophobic chromatography, enzyme assays using immobilised antibodies, nucleic acids or antigens, enzyme catalysis on solid phase supports, food screening for
  • Fig. 1 illustrates with the solid phase inside a syringe
  • Fig.2 shows the use of a cartridge
  • Fig. 3 shows a pipette
  • Figs. 4, 5 and 6 show alternative cartridges
  • Figs. 7, 8 and 9 show different disc arrangements.
  • a syringe (1) having a moveable piston (2) has an adsorbent solid phase (3) held within it.
  • the nozzle (4) is placed within the liquid from which material is to be separated and the piston withdrawn to suck up the liquid through (3).
  • the piston is depressed the liquid is forced back over (3) and this process can be repeated if desired so that there is better adsorption of material from the liquid.
  • the syringe (5) with a piston (6) has nozzle (7) placed in cartridge (8) containing a solid adsorbent and the cartridge (8) has its inlet (9) placed in the liquid from which material is to be separated.
  • the piston (6) is withdrawn the liquid is drawn up through the cartridge and material is adsorbed, when the piston is depressed the liquid is forced back over the adsorbent in the cartridge so that there is better adsorption of material from the liquid.
  • the adsorbent material (10) can be in the form of frits or beads and can fill the cartridge.
  • a by-pass channel (11) round the outside of the solid adsorbent so that larger particles can pass up and down without clogging.
  • each disc consists of an adsorbent membrane
  • the discs can have large pores as illustrated in fig. 7 and can have cut away sections as shown in fig. 8 to prevent blocking.
  • the discs can be stacked on top the other and can have a raised lip (14) as shown in fig. 9 so that the discs are only in contact through this lip.
  • a pipette (15) has an aerosol plug (16) to prevent contamination and contains a plug (16) of adsorbent material such as a porous plastic material as shown.
  • adsorbent material such as a porous plastic material as shown.
  • the tip of the pipette (17) is placed in the liquid and liquid is sucked up over the plug (16), by blowing down the pipette the liquid is forced back over the plug (16) so that there is better adsorption of material from the liquid.
  • the adsorbed material can be removed from the solid phase by conventional elution methods.
  • polystyrene porous carboxylated beads 200 - 500 microns or 16 - 50 mesh size
  • plastic mesh with pore sizes of about 100 microns.
  • the dilution buffer can be any hypotonic solution that causes lysis of the red blood cell fraction, but maintains the integrity of nuclei, white blood cells or chromatin.
  • the nuclei became immobilised on the beads and the lysed blood was taken to waste. Direct elution of the nuclear DNA was achieved using hot water.
  • the eluate from the first cartridge was then further processed using another cartridge containing a solid-phase with poly imidazole groups.
  • To collect the white blood cell fraction the same solution is made isotonic with saline and the cells were captured in a similar manner.
  • polystyrene porous carboxylated beads 200 - 500 microns or 16 - 50 mesh size
  • polystyrene porous carboxylated beads 200 - 500 microns or 16 - 50 mesh size
  • agarose was treated with carbonyldiimidazole in anhydrous organic solvent and then left in water at pH 3 to maintain the imidazole groups.
  • the derivatised agarose was placed in a cartridge and the supernatant from a plasmid alkaline lysis preparation was sucked up and down immobilising the plasmid DNA on the beads at pH 5. After washing, the plasmid DNA was eluted with lOmM Tris HC1, pH 9.
  • the frit and nuclei was then washed to remove residual proteins using deionised water or chaotropes or alcohols or detergents such SDS or Tween 20 or combinations or lactic and salicylic acids or their salts, or poly phosphates or per chlorates and either eluted off using hot water or alkaline solutions of detergents or further purified inside the cartridge using chaotropic agents or proteases.
  • deionised water or chaotropes or alcohols or detergents such SDS or Tween 20 or combinations or lactic and salicylic acids or their salts, or poly phosphates or per chlorates
  • a plug of porous polyethylene was derivatised with imidazole groups and inserted into the tip of a standard 1ml pipette tip.
  • a further non derivatised plug was inserted at the top to act as an aerosol and liquid barrier to prevent contamination of the pipette.
  • a buccal scrape was taken and mixed with 0.2M guanidine isothiocyanate, 3% Tween 20, Proteinase K and 50mM MES pH5 at 30°C for 15 minutes. The mixture was then sucked up and down the tip several times allowing the DNA to bind to the derivatised plug.
  • the plug was washed with ImM MES pH5 and then the DNA eluted with lOmM Tris. HCI pH9. The same protocol was repeated using 0.01% to 10% SDS with or without salts and buffers. Fast degradation of the buccal cells can also be achieved using salicylic acid, lactic acid, or MgCl at concentrations of 0.05 to 5M. Combinations of the above salts and reagents can also be used.
  • Example 6 1 gram of carboxylated polystyrene beads with a diameter of about 60 microns or 200 to 400 mesh was suspended in a hypotonic solution of ammonium bicarbonate 1 OmM with 0.1 % Tween 20 pH9. A five fold excess of this suspension was added to a 5ml blood sample and mixed once. The beads captured the nuclei and sedimented. After several washes with water, the DNA was eluted with hot water. To concentrate the DNA the equipment of fig. 2 was used with the packing of fig. 6 and the DNA was captured on a porous disc in the cartridge and subsequently eluted off in a small volume and analysed using PCR or Restriction Digestion
  • Example 7 Removal and purification of human IgG from serum An agarose gel coupled to Protein A was placed in the cartridge of fig. 2 and washed with phosphate buffered saline. A solution containing human IgG in serum was sucked up and down the solid phase until all the IgG was bound. After washing the solid phase with PBS, the IgG was eluted with 0.1 M glycine, 0.1 5M NaCl, pH2.8 and immediately neutralised with Tris. HCI.
  • Example 8 Purification and isolation of specific white blood cell types from whole blood
  • Non-porous glass particles of 175 microns were coupled to CD4 monoclonal antibodies and the solid phase placed in a cartridge as in Example 4 with 80micron frits. A diluted solution of Buffy Coat was sucked slowly up and down through the glass beads immobilising the T cell sub-population which could be released.
  • Example 9 Recombinant protein purification An agarose gel containing Iminodiacetic acid-Nickel ion groups was packed into a cartridge as in Example 4.
  • a bacterial lysate containing a recombinant protein possessing a 6 histidine tail was sucked up and down the cartridge and the protein was bound to the co-ordinated nickel. Release of the protein was effected by eluting with 0.5M Imidazole pH 6.
  • a cartridge as in fig. 2 was packed with 60 micron silica and a sample of serum diluted 5 times with 6M guanidine isothiocyanate, 0.1 % Tween 20, 20mM EDTA, lOOmM Tris. HCI pH6 was sucked up and down through the solid phase. After washing the solid phase with isopropanol and drying the RNA was eluted using water at 60C.
  • a cartridge as in fig. 2 was packed with 60 micron silica and a sample of a PCR reaction diluted 5 times with 6M guanidine isothiocyanate, 0. 1 % Tween 20, 20mM
  • Fresh liver was homogenised in a mixture of 50% Phenol containing 6M Guanidine isothiocyanate, lOmM DTT, 0.1 M Sodium Acetate pH 4. Chloroform was added to separate the phases and the top layer containing the RNA was sucked up and down through a cartridge of fig. 2 containing 60micron silica. The silica was washed with alcohol, air dried and the RNA eluted with hot water ready for processing.
  • a cartridge was packed with COOH polystyrene beads coupled to oligo dT 30 5'
  • a sample of white blood cells prepared earlier in a cartridge were treated with an excess of 1% SDS, 0.5M LiCl, lOmM DTT, lOmM Tris. HCI pH 7.5 and sucked up and down through the affinity resin several times to shear the DNA and bind the mRNA. The resin was then washed in 0.1 M LiCl and air dried. Elution of mRNA was performed by hot water.
  • Example 4 that was coupled to oligo dT30 and used for binding less than 5 micrograms ofmRNA.
  • Streptavidin was immobilised onto porous frits by mixing the protein in 0.1 M sodium phosphate buffer with 0.01% glutaldehyde pH7 as in example 4. Biotinylated primers used to generate a PCR product were then isolated on the immobilised streptavidin. The PCR product was then made single stranded using heat or 0.1 M NaOH and used for sequencing or probe analysis.
  • Example 15 Use of electrodes, static charge, induction, electrophoresis to isolate DNA or RNA

Landscapes

  • Physics & Mathematics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Selon cette invention, un procédé pour extraire des biomolécules telles que l'ADN à partir d'un mélange liquide consiste à faire monter et descendre le liquide à travers une phase solide comprenant une substance adsorbant ces biomolécules.
EP00937072A 1999-06-08 2000-06-07 Dispositif de traitement d'echantillons Withdrawn EP1183514A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9913275.5A GB9913275D0 (en) 1999-06-08 1999-06-08 Sample processing device
GB9913275 1999-06-08
PCT/GB2000/002211 WO2000075623A1 (fr) 1999-06-08 2000-06-07 Dispositif de traitement d'echantillons

Publications (1)

Publication Number Publication Date
EP1183514A1 true EP1183514A1 (fr) 2002-03-06

Family

ID=10854928

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00937072A Withdrawn EP1183514A1 (fr) 1999-06-08 2000-06-07 Dispositif de traitement d'echantillons

Country Status (6)

Country Link
EP (1) EP1183514A1 (fr)
JP (1) JP2003501644A (fr)
AU (1) AU778440B2 (fr)
CA (1) CA2375449A1 (fr)
GB (1) GB9913275D0 (fr)
WO (1) WO2000075623A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10319045A1 (de) * 2003-04-25 2004-12-09 november Aktiengesellschaft Gesellschaft für Molekulare Medizin Vorrichtung und Verfahren zur Aufbereitung Biopolymerhaltiger Flüssigkeiten
WO2005011867A2 (fr) 2003-07-31 2005-02-10 Handylab, Inc. Traitement d'echantillons contenant des particules
DE502004008840D1 (de) * 2003-12-09 2009-02-26 Bgb Analytik Ag Vorrichtung zur probenvorbereitung
JP4090443B2 (ja) * 2004-02-24 2008-05-28 株式会社日立ハイテクノロジーズ 核酸回収器具、その部品、及び核酸回収器具の生産方法
US8852862B2 (en) 2004-05-03 2014-10-07 Handylab, Inc. Method for processing polynucleotide-containing samples
JP4699868B2 (ja) * 2005-11-04 2011-06-15 株式会社日立ハイテクノロジーズ 核酸精製方法及び核酸精製器具
US10900066B2 (en) 2006-03-24 2021-01-26 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
ES2587007T3 (es) 2006-03-24 2016-10-20 Handylab, Inc. Sistema integrado para procesar muestras microfluídicas, y métodos de uso del mismo
US8883490B2 (en) 2006-03-24 2014-11-11 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US11806718B2 (en) 2006-03-24 2023-11-07 Handylab, Inc. Fluorescence detector for microfluidic diagnostic system
US7998708B2 (en) 2006-03-24 2011-08-16 Handylab, Inc. Microfluidic system for amplifying and detecting polynucleotides in parallel
EP2091647A2 (fr) 2006-11-14 2009-08-26 Handylab, Inc. Système microfluidique utilisé pour amplifier et détecter des polynucléotides en parallèle
JP4959450B2 (ja) * 2007-07-10 2012-06-20 株式会社日立ハイテクノロジーズ 化学分析装置
US8287820B2 (en) 2007-07-13 2012-10-16 Handylab, Inc. Automated pipetting apparatus having a combined liquid pump and pipette head system
WO2009012185A1 (fr) 2007-07-13 2009-01-22 Handylab, Inc. Matières absorbant les polynucléotides, et procédés d'utilisation de celles-ci
US8182763B2 (en) 2007-07-13 2012-05-22 Handylab, Inc. Rack for sample tubes and reagent holders
US8105783B2 (en) 2007-07-13 2012-01-31 Handylab, Inc. Microfluidic cartridge
US9186677B2 (en) 2007-07-13 2015-11-17 Handylab, Inc. Integrated apparatus for performing nucleic acid extraction and diagnostic testing on multiple biological samples
US7759112B2 (en) * 2007-10-31 2010-07-20 Akonni Biosystems, Inc. Apparatus, system, and method for purifying nucleic acids
JP2014511107A (ja) * 2010-12-29 2014-05-08 シーユービーアールシー コーポレイション 抽出ピペット
ES2617599T3 (es) 2011-04-15 2017-06-19 Becton, Dickinson And Company Termociclador microfluídico de exploración en tiempo real y métodos para termociclado sincronizado y detección óptica de exploración
WO2013067202A1 (fr) 2011-11-04 2013-05-10 Handylab, Inc. Dispositif de préparation d'échantillons de polynucléotides
JP5363604B2 (ja) * 2012-03-21 2013-12-11 株式会社日立ハイテクノロジーズ 化学分析装置
CN105779277A (zh) * 2015-01-13 2016-07-20 温和心 核酸提取吸管
CN106990193B (zh) * 2017-04-28 2019-12-13 广东联捷生物科技有限公司 固相萃取样品前处理装置及处理方法
GB2628351A (en) * 2023-03-20 2024-09-25 Markes International Ltd A sorbent device for sorptive sampling

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0416326B1 (fr) * 1989-09-06 1994-05-25 Hewlett-Packard Company Dispositif pour l'extraction automatisée d'une substance à l'aide d'une phase sorbente solide
US6042787A (en) * 1990-02-04 2000-03-28 Pawliszyn; Janusz B. Device for solid phase microextraction and desorption
AU2310992A (en) * 1991-07-12 1993-02-11 Toxi Lab, Inc. Method and apparatus for improved solid phase extraction
US5453382A (en) * 1991-08-05 1995-09-26 Indiana University Foundation Electrochromatographic preconcentration method
US5391298B1 (en) * 1993-03-05 1997-10-28 Minnesota Mining & Mfg Method for performing a solid-phase extraction under pressurized conditions
US5565622A (en) * 1994-09-15 1996-10-15 Hewlett-Packard Co., Legal Dept. Reduced solvent solid phase extraction
DE19516179C1 (de) * 1995-05-03 1996-11-21 Karl Prof Dr Cammann Chemisch-analytische Probenahme-Vorrichtung mit integrierter Dosimeter- und Funktionsanzeige
WO1998026872A1 (fr) * 1996-12-18 1998-06-25 Ansys, Inc. Procede pour la mise en oeuvre d'analyses et d'extractions de composants d'interet dans des echantillons de fluides
NO305370B1 (no) * 1997-09-08 1999-05-18 Knut Rudi Apparat for rensing av organisk materiale og fremgangsmÕte for rensing av organisk materiale

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0075623A1 *

Also Published As

Publication number Publication date
GB9913275D0 (en) 1999-08-04
CA2375449A1 (fr) 2000-12-14
AU5236300A (en) 2000-12-28
JP2003501644A (ja) 2003-01-14
AU778440B2 (en) 2004-12-02
WO2000075623A1 (fr) 2000-12-14

Similar Documents

Publication Publication Date Title
AU778440B2 (en) Sample processing device
CN107249746B (zh) 用于收集核酸样本的系统和方法
CN1230440C (zh) 核酸的分离
US9506847B2 (en) Method and system for selective isolation of target biological molecules in a general purpose system
CA2703950C (fr) Appareil, systeme et procede de purification d'acides nucleiques
JP3527884B2 (ja) 核酸の単離及び精製方法並びにその装置
US20080102493A1 (en) Isolation of RNA and DNA from a biological sample
US20080153078A1 (en) System for isolating biomolecules from a sample
CA2983623C (fr) Procede et dispositif d'extraction d'acides nucleiques
KR20120044918A (ko) 핵산 정제
US20030203491A1 (en) Gravitational flow purification system
KR20170012806A (ko) 다이렉트 용리 반응에 의한 핵산 추출 및 증폭 방법
JP2008519986A (ja) 生物学的物質の精製のための器具及び方法
JP2006311803A (ja) 核酸精製方法、及び核酸精製器具
KR20240027088A (ko) 범용 분석 카트리지 및 사용 방법
US8685742B2 (en) Apparatus and method for the more efficient isolation of nucleic acids
US20230383281A1 (en) Filtration methods and devices for fast nucleic acid extraction
CN223433451U (zh) 一种磁珠法提取核酸的微流控芯片
RU2595374C2 (ru) Способ автоматизированного выделения с одновременной очисткой нуклеиновых кислот из нескольких биологических образцов
US20030228600A1 (en) DNA isolation method and kit
HK40039785A (en) System and method for collecting a sample of nucleic acid
JP2001299341A (ja) 改良されたリボ核酸の単離方法
CA2464462A1 (fr) Procede d'isolement d'acides nucleiques et appareil pour sa mise en oeuvre

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011213

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: INVITROGEN CORPORATION

17Q First examination report despatched

Effective date: 20071122

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080603